TPSAB1 expression	Melanoma	TPSAB1 expression	Melanoma	ex-vivo autologous dendritic cells vaccine Sensitive: C3 – Early Trials ex-vivo autologous dendritic cells vaccine Sensitive : C3	ex-vivo autologous dendritic cells vaccine Sensitive: C3 – Early Trials ex-vivo autologous dendritic cells vaccine Sensitive : C3
CD9 expression	Melanoma	CD9 expression	Melanoma	ex-vivo autologous dendritic cells vaccine Sensitive: C3 – Early Trials ex-vivo autologous dendritic cells vaccine Sensitive : C3	ex-vivo autologous dendritic cells vaccine Sensitive: C3 – Early Trials ex-vivo autologous dendritic cells vaccine Sensitive : C3
CSF2 expression	Melanoma	CSF2 expression	Melanoma	ex-vivo autologous dendritic cells vaccine Sensitive: C3 – Early Trials ex-vivo autologous dendritic cells vaccine Sensitive : C3	ex-vivo autologous dendritic cells vaccine Sensitive: C3 – Early Trials ex-vivo autologous dendritic cells vaccine Sensitive : C3
STAT2 expression	Melanoma	STAT2 expression	Melanoma	ex-vivo autologous dendritic cells vaccine Sensitive: C3 – Early Trials ex-vivo autologous dendritic cells vaccine Sensitive : C3	ex-vivo autologous dendritic cells vaccine Sensitive: C3 – Early Trials ex-vivo autologous dendritic cells vaccine Sensitive : C3
CD70 expression	Cutaneous T-cell Lymphoma	CD70 expression	Cutaneous T-cell Lymphoma	ARGX-110 Sensitive: C3 – Early Trials ARGX-110 Sensitive : C3	ARGX-110 Sensitive: C3 – Early Trials ARGX-110 Sensitive : C3
CD70 expression	Acute Myelogenous Leukemia	CD70 expression	Acute Myelogenous Leukemia	venetoclax + ARGX-110 Sensitive: D – Preclinical venetoclax + ARGX-110 Sensitive : D	venetoclax + ARGX-110 Sensitive: D – Preclinical venetoclax + ARGX-110 Sensitive : D
CD70 expression	Solid Tumor	CD70 expression	Solid Tumor	CAT-248 Sensitive: D – Preclinical CAT-248 Sensitive : D	CAT-248 Sensitive: D – Preclinical CAT-248 Sensitive : D

CD70 inhibitor

CD70 inhibitor

Associations(7)

Associations
(7)